Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: brain ; RECEPTOR ; ANGIOGENESIS ; APOPTOSIS ; CELLS ; EXPRESSION ; GROWTH ; IN-VITRO ; INVASION ; proliferation ; SURVIVAL ; tumor ; TUMOR-CELLS ; Germany ; human ; IN-VIVO ; INHIBITION ; KINASE ; THERAPY ; VITRO ; DISTINCT ; TUMORS ; validation ; LINES ; MICE ; TIME ; IDENTIFICATION ; METASTASIS ; CELL-LINE ; leukemia ; LINE ; MIGRATION ; OVEREXPRESSION ; CANCER-THERAPY ; GLIOMAS ; INVITRO ; CELL-GROWTH ; signaling ; BRAIN-TUMORS ; GLIOMA ; PROTOONCOGENE ; LEVEL ; cell migration ; in vivo ; GLIOBLASTOMA ; receptor tyrosine kinase ; GAS6
    Abstract: Malignant gliomas remain incurable brain tumors because of their diffuse-invasive growth. So far, the genetic and molecular events underlying gliomagenesis are poorly understood. In this study, we have identified the receptor tyrosine kinase Axl as a mediator of glioma growth and invasion. We demonstrate that Axl and its ligand Gas6 are overexpressed in human glioma cell lines and that Axl is activated under baseline conditions. Furthermore, AxI is expressed at high levels in human malignant glioma. Inhibition of Axl signaling by overexpression of a dominant-negative receptor mutant (AXL-DN) suppressed experimental gliomagenesis (growth inhibition 〉 85%, P 〈 0.05) and resulted in long-term survival of mice after intracerebral glioma cell implantation when compared with Axl wild-type (AXL-WT) transfected tumor cells (survival times: AXL-WT, 10 days; AXL-DN, 〉 72 days). A detailed analysis of the distinct hallmarks of glioma pathology, such as cell proliferation, migration, and invasion and tumor angiogenesis, revealed that inhibition of Axl signaling interfered with cell proliferation (inhibition 30% versus AXL-WT), glioma cell migration (inhibition 90% versus mock and AXL-WT, P 〈 0.05), and invasion (inhibition 62% and 79% versus mock and AXL-WT, respectively; P 〈 0.05). This study describes the identification, functional manipulation, in vitro and in vivo validation, and preclinical therapeutic inhibition of a target receptor tyrosine kinase mediating glioma growth and invasion. Our findings implicate Axl in gliomagenesis and validate it as a promising target for the development of approaches toward a therapy of these highly aggressive but, as yet, therapy-refractory, tumors
    Type of Publication: Journal article published
    PubMed ID: 16585512
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...